BCAB Quote, Financials, Valuation and Earnings

Context Therapeutics, Inc. has a net margin of -96.24% compared to BioAtla, Inc.'s net margin of --. BioAtla, Inc.'s return on equity of -567.84% beat Context Therapeutics, Inc.'s return on equity of -31.05%.

BioAtla, Inc. has a consensus price target of $10.00, signalling upside risk potential of 1227.32%. On the other hand Context Therapeutics, Inc. has an analysts' consensus of $5.33 which suggests that it could grow by 319.95%. Given that BioAtla, Inc. has higher upside potential than Context Therapeutics, Inc., analysts believe BioAtla, Inc. is more attractive than Context Therapeutics, Inc..

BioAtla, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Context Therapeutics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

BioAtla, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Context Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioAtla, Inc. pays -- of its earnings as a dividend. Context Therapeutics, Inc. pays out -- of its earnings as a dividend.

BioAtla, Inc. quarterly revenues are --, which are smaller than Context Therapeutics, Inc. quarterly revenues of --. BioAtla, Inc.'s net income of -$15.8M is lower than Context Therapeutics, Inc.'s net income of -$9.7M. Notably, BioAtla, Inc.'s price-to-earnings ratio is -- while Context Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioAtla, Inc. is 3.86x versus -- for Context Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

CEL-SCI Corp. has a net margin of -96.24% compared to BioAtla, Inc.'s net margin of --. BioAtla, Inc.'s return on equity of -567.84% beat CEL-SCI Corp.'s return on equity of -266.61%.

BioAtla, Inc. has a consensus price target of $10.00, signalling upside risk potential of 1227.32%. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 765.58%. Given that BioAtla, Inc. has higher upside potential than CEL-SCI Corp., analysts believe BioAtla, Inc. is more attractive than CEL-SCI Corp..

BioAtla, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.259%.

BioAtla, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioAtla, Inc. pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.

BioAtla, Inc. quarterly revenues are --, which are smaller than CEL-SCI Corp. quarterly revenues of --. BioAtla, Inc.'s net income of -$15.8M is lower than CEL-SCI Corp.'s net income of -$5.7M. Notably, BioAtla, Inc.'s price-to-earnings ratio is -- while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioAtla, Inc. is 3.86x versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.

IGC Pharma, Inc. has a net margin of -96.24% compared to BioAtla, Inc.'s net margin of -953.4%. BioAtla, Inc.'s return on equity of -567.84% beat IGC Pharma, Inc.'s return on equity of -94.42%.

BioAtla, Inc. has a consensus price target of $10.00, signalling upside risk potential of 1227.32%. On the other hand IGC Pharma, Inc. has an analysts' consensus of $3.88 which suggests that it could grow by 1191.67%. Given that BioAtla, Inc. has higher upside potential than IGC Pharma, Inc., analysts believe BioAtla, Inc. is more attractive than IGC Pharma, Inc..

BioAtla, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison IGC Pharma, Inc. has a beta of 0.242, suggesting its less volatile than the S&P 500 by 75.839%.

BioAtla, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioAtla, Inc. pays -- of its earnings as a dividend. IGC Pharma, Inc. pays out -- of its earnings as a dividend.

BioAtla, Inc. quarterly revenues are --, which are smaller than IGC Pharma, Inc. quarterly revenues of $191K. BioAtla, Inc.'s net income of -$15.8M is lower than IGC Pharma, Inc.'s net income of -$1.8M. Notably, BioAtla, Inc.'s price-to-earnings ratio is -- while IGC Pharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioAtla, Inc. is 3.86x versus 22.51x for IGC Pharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals, Inc. has a net margin of -96.24% compared to BioAtla, Inc.'s net margin of -255.85%. BioAtla, Inc.'s return on equity of -567.84% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

BioAtla, Inc. has a consensus price target of $10.00, signalling upside risk potential of 1227.32%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -83.96%. Given that BioAtla, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe BioAtla, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..

BioAtla, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.

BioAtla, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. BioAtla, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

BioAtla, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. BioAtla, Inc.'s net income of -$15.8M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, BioAtla, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 8.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioAtla, Inc. is 3.86x versus 10.30x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.